• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by AIkido Pharma Inc.

    12/28/22 4:14:12 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AIKI alert in real time by email
    SC 13D 1 ea170889-13dwool_dominari.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ______)* 

     

     

     

     

     

      Dominari Holdings Inc.  
      (Name of Issuer)  
         
      Common Stock, par value $0.0001 per share  
      (Title of Class of Securities)  
         
      0088753043  
      (CUSIP Number)  
         
     

    Scott A. Mautner, Esq.

    Harrington Ocko & Monk, LLP

    81 Main Street, Suite 215

    White Plains, NY 10601

    (914) 686-4800

     
      (Name, Address and Telephone Number of Person Authorized to  
      Receive Notices and Communications)  
         
      December 19, 2022  
      (Date of Event Which Requires Filing of this Statement)  

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043
    1   

    NAME OF REPORTING PERSON

     

    Kyle Michael Wool

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

    4  

    SOURCE OF FUNDS

     

    PF, OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH REPORTING

    PERSON WITH

      7   

    SOLE VOTING POWER

     

    6,512 (1)

      8  

    SHARED VOTING POWER

     

    272,792 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    6,512 (1)

      10  

    SHARED DISPOSITIVE POWER

     

    272,792 (1)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    279,304

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 

     

    ☐ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.09% (2)

    14  

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)Of the 272,792 shares reported as beneficially owned with shared voting and dispositive power, 190,568 shares are beneficially owned directly by Mr. Wool and 82,224 shares are beneficially owned directly by Ms. Yu, Mr. Wool’s spouse. Of the 6,512 shares reported as beneficially owned with sole voting and dispositive power, 1,477 shares are held by Catatonk Creek, LLC, of which Mr. Wool is the sole member, 1,476 shares are held by Tioga 22, LLC, of which Mr. Wool is the sole member, and 3,559 shares are held in a UTMA account for the benefit of a minor relative.
    (2)Calculated based on 5,485,096 shares of common stock of the Issuer outstanding as of November 9, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

     

    2

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043
    1   

    NAME OF REPORTING PERSON

     

    Soo Yu

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

    4  

    SOURCE OF FUNDS

     

    PF, OO

    5  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) 

     

    ☐

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH REPORTING

    PERSON WITH

      7   

    SOLE VOTING POWER

     

    1,477 (1)

      8  

    SHARED VOTING POWER

     

    272,792 (1)

      9  

    SOLE DISPOSITIVE POWER

     

    1,477 (1)

      10  

    SHARED DISPOSITIVE POWER

     

    272,792 (1)

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    281,799 (1)

    12  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 

     

    ☐ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.00% (2)

    14  

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)Of the 272,792 shares reported as beneficially owned with shared voting and dispositive power, 82,224 shares are beneficially owned directly by Ms. Yu and 190,568 shares are beneficially owned directly by Mr. Wool, Ms. Yu’s spouse. The 1,477 shares reported as beneficially owned with sole voting and dispositive power are held by Dongam, LLC, of which Ms. Yu is the sole member.
    (2)Calculated based on 5,485,096 shares of common stock of the Issuer outstanding as of November 9, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

     

    3

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043

     

    Item 1. Security and Issuer.

     

    This statement on Schedule 13D relates to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of Dominari Holdings Inc., a Delaware corporation (the “Issuer”). The address of the Issuer’s principal executive offices is One Rockefeller Plaza, 11th Floor, New York, New York 10020. On December 22, 2022, the Issuer announced that it changed its name from AIkido Pharma Inc. to Dominari Holdings Inc.

     

    Item 2. Identity and Background.

     

    (a) This statement on Schedule 13D is being filed jointly by Kyle Michael Wool and Soo Yu as individuals, each of whom is referred to herein, together, as the “Reporting Persons.” The Reporting Persons are husband and wife.

     

    (b) The principal business address of the Reporting Persons is c/o Dominari Holdings Inc., One Rockefeller Plaza, 11th Floor, New York, New York 10020.

     

    (c) Mr. Wool serves as non-executive chairman of Revere Securities LLC and Ms. Yu is the Managing Director of International Private Client Services for Revere Securities LLC. The address of Revere Securities LLC is 650 Fifth Avenue, 35th Floor, New York, New York 10019. Each of Mr. Wool and Ms. Yu also serve as a director on the board of directors of the Issuer. Mr. Wool is also a special advisor to the Issuer.

     

    (d) During  the last five years, neither of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e) During  the last five years, neither of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The Reporting Persons are citizens of the United States.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Except for the following grants by the Issuer to the Reporting Persons for their service as directors on the board of directors of the Issuer, all of the shares of Common Stock held by the Reporting Persons to which this Schedule 13D relates were purchased using the personal funds of the Reporting Persons in open market purchases:

     

    ●On July 31, 2021, Mr. Wool was granted 25,000  shares of Common Stock pursuant to the Issuer’s 2014 Equity Incentive Plan. This grant of restricted stock vested immediately.

     

    ●On August 26, 2022, Mr. Wool was granted 70,588 shares of restricted stock, under the Issuer’s 2014 Equity Incentive Plan, pursuant to a Stock Bonus Award Agreement between Mr. Wool and the Issuer, in exchange for his voluntary surrender of the 70,588 non-qualified stock options (as adjusted for the June 7, 2022 reverse split) that were previously granted to Mr. Wool on May 2, 2022, which stock options were cancelled. This grant of restricted stock vested immediately.

     

    ●On August 26, 2022, Mr. Wool was granted 8,000 shares of restricted stock, under the Issuer’s 2014 Equity Incentive Plan, pursuant to a Stock Bonus Award Agreement between Mr. Wool and the Issuer. This grant of restricted stock vested immediately

     

    ●On August 26, 2022, Ms. Yu was granted 8,000 shares of restricted stock pursuant to the Issuer’s 2014 Equity Incentive Plan. This grant of restricted stock vested immediately.

     

    Item 4. Purpose of Transaction.

     

    The Reporting Persons acquired beneficial ownership of the Common Stock for investment purposes.

     

    The Reporting Persons may acquire additional shares of Common Stock or other securities of the Issuer or sell or otherwise dispose of any or all of the Common Stock or other securities of the Company beneficially owned by them.

     

    Both Mr. Wool and Ms. Yu are members of the board of directors of the Issuer and Mr. Wool is a special advisor to the Issuer.

     

    4

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043

     

    On October 17, 2022, Mr. Wool entered into an Amended and Restated Services Agreement with Dominari Financial Inc., the Issuer’s wholly owned subsidiary (“DFI”), for an initial term of five years, renewable thereafter for additional one-year periods on an annual basis (as amended, the “Services Agreement”). Under the terms of the Services Agreement, Mr. Wool will serve as a consultant to DFI until his employment and registration as a registered representative with the Financial Industry Regulatory Authority have been terminated with his current employer. Upon such terminations, Mr. Wool will assume the role of Chief Executive Officer of DFI, with the other duties, responsibilities and authority as may be assigned to him by the Chief Executive Officer of the Issuer or the board of directors of DFI. The Services Agreement provides for the payment of an annual base salary of $500,000 to Mr. Wool, and an annual bonus (“Annual Bonus”) payable in cash and in shares of Common Stock as a performance-based award (the “Stock Bonus”) of shares of Common Stock under the Issuer’s 2022 Equity Incentive Plan (the “2022 Incentive Plan”), in three installments, based on the Issuer meeting or exceeding certain annual revenue amounts during specified calendar years. The issuance of any shares of Common Stock to Mr. Wool under the 2022 Incentive Plan, as the Stock Bonus portion of the Annual Bonus, is expressly conditioned on stockholder approval of the 2022 Incentive Plan on or before October 7, 2023. If such stockholder approval is not obtained on or before October 7, 2023, the Stock Bonus portion of the Annual Bonus will be forfeited and DFI will make a one-time cash payment to Mr. Wool equal to the product obtained by multiplying (i) the total amount of 463,678 shares of Common Stock which would have been awarded to Mr. Wool, if all of the shares of Common Stock subject to the Stock Bonus had been issued to him, and (ii) the closing price of the Common Stock on the Nasdaq Capital Market on the trading day immediately preceding October 7, 2023.

     

    The Services Agreement also provides for the support of an administrative assistant to Mr. Wool, reimbursement of certain specified expenses, and entitlement to participate in any of DFI’s benefit plans offered to senior executives.

     

    Upon a termination of the Services Agreement (i) by DFI without “Cause” or (ii) by Mr. Wool for “Good Reason” or by notice within forty (40) days of a “Change in Control Transaction” (as such terms are defined in the Services Agreement), Mr. Wool will be entitled to receive (i) a lump sum payment equal to twelve (12) months base salary at the then current rate, (ii) payments by DFI of a portion of the cost of continuation of group health coverage under COBRA, and (iii) a pro-rated portion of any bonus payments to which Mr. Wool would otherwise been entitled as of the date of his termination.

     

    The foregoing description of the Services Agreement is qualified in its entirety by reference to the text of the Services Agreement, which is attached hereto as Exhibit 1.01 and incorporated herein by reference.

     

    Except as disclosed in this Item 4, the Reporting Persons have no current plans or proposals which relate to or would result in any of the events described in Items (a) through (j) of the instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)-(b) The Reporting Persons have shared voting and dispositive power over 272,792 shares of Common Stock of the Issuer as a result of their status as husband and wife. Of the 272,792 shares of Common Stock that the Reporting Persons have shared voting and dispositive power over, 190,568 shares are beneficially owned directly by Mr. Wool and 82,224 shares are beneficially owned directly by Ms. Yu. In addition, Mr. Wool has sole voting and dispositive power over 6,512 shares of Common Stock, which he holds indirectly as follows: 1,477 shares are held by Catatonk Creek, LLC, of which Mr. Wool is the sole member; 1,476 shares are held by Tioga 22, LLC, of which Mr. Wool is the sole member; and 3,559 shares are held in a UTMA account for the benefit of a minor relative. Ms. Yu has sole voting and dispositive power over an additional 1,477 shares, which are held by Dongam, LLC, of which Ms. Yu is the sole member. Accordingly, on an individual basis, Mr. Wool and Ms. Yu beneficially own 5.09% and 5.00%, respectively, of the outstanding Common Stock of the Issuer, based on 5,485,096 shares of Common Stock of the Issuer outstanding as of November 9, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

     

    On June 7, 2022, the Issuer effected a seventeen-for-one (17-for-1) reverse stock split of its Common Stock. All references to Common Stock, stock options restricted stock awards, and related information herein reflect the effect of the reverse stock split.

     

    (c) The following transactions in the shares of Common Stock were conducted by the Reporting Persons within the past sixty (60) days:

     

    Date of Purchase  Number of
    Shares
       Price
    Per Share
       Nature of Transaction
    12/7/2022   5,000   $3.4766   Open Market Purchase
    12/8/2022   5,000   $3.562   Open Market Purchase
    12/9/2022   5,000   $3.683   Open Market Purchase
    12/12/2022   5,000   $3.625   Open Market Purchase
    12/13/2022   5,000   $3.697   Open Market Purchase
    12/14/2022   4,500   $3.69   Open Market Purchase
    12/15/2022   5,000   $3.687   Open Market Purchase
    12/16/2022   5,000   $3.705   Open Market Purchase
    12/19/2022   5,000   $3.593   Open Market Purchase
    12/20/2022   6,000   $3.588   Open Market Purchase

     

    (d) None.

     

    5

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    The information provided or incorporated by reference in Items 2, 3, 4 and 5 of this Schedule 13D, is hereby incorporated herein by this reference thereto.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit 1.01   Amended and Restated Services Agreement, effective as of October 17, 2022, by and between Dominari Financial Inc. and Kyle Wool incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K (File No. 000-05576), filed on October 21, 2022.
    Exhibit 1.02   Amendment to Amended and Restated Services Agreement, effective as of October 19, 2022, by and between Dominari Financial Inc. and Kyle Wool incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K (File No. 000-05576), filed on October 21, 2022.
    Exhibit 1.03   AIkido Pharma Inc. 2014 Equity Incentive Plan incorporated by reference to Exhibit 10.1 to the Issuer’s Registration Statement on Form S-8 (File No. 333-197429), filed on July 15, 2014.
    Exhibit 1.04   AIkido Pharma Inc. 2022 Equity Incentive Plan incorporated by reference to Annex A to the Issuer’s Definitive Proxy Statement (File No. 000-05576), filed on October 21, 2022.
    Exhibit 1.05   Joint Filing Agreement, dated as of December 28, 2022, between the Reporting Persons.

     

    6

     

     

    SCHEDULE 13D

     

    CUSIP No. 0088753043

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: December 28, 2022 

     

     

    /s/ Kyle Wool

      Kyle Wool
       
     

    /s/ Soo Yu

      Soo Yu

     

     

    7

     

     

    Get the next $AIKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIKI

    DatePrice TargetRatingAnalyst
    10/11/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AIKI
    Leadership Updates

    Live Leadership Updates

    See more
    • AIkido Pharma Inc. Appoints New Director, Soo Yu

      New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

      6/10/22 4:15:00 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

      NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

      9/14/21 9:22:00 AM ET
      $AIKI
      $DATS
      Specialty Chemicals
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications
    • AIkido Pharma Provides Business Update

      NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

      4/5/21 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Financials

    Live finance-specific insights

    See more
    • AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

      NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.  This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob

      6/23/21 10:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AIKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/26/23 6:43:23 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Dominari Holdings Provides Update on Share Repurchase Program

      NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

      12/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

      NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

      12/22/22 8:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

      Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

      11/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/22/23 6:00:41 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

      HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

      10/11/21 6:14:44 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AIkido Pharma Inc.

      SC 13D - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:15:22 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:05:18 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      7/6/23 4:30:08 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    SEC Filings

    See more
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      12/18/23 4:05:35 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      11/13/23 6:05:12 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by AIkido Pharma Inc.

      10-Q - Dominari Holdings Inc. (0000012239) (Filer)

      11/6/23 4:47:02 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary